Nadia D Ali1, Kristen Donohue2, Shadi Zandieh3, Chunxia Chen4, Dirk Moore4, Elizabeth Poplin3,5, Mihir M Shah2,6, John Nosher7, Bin Gui6, Salma K Jabbour8, Kristen Spencer3,5, Darren R Carpizo2,6. 1. Department of Medicine, Section of Hematology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA. 2. Departments of Surgery. 3. Departments of Medical Oncology. 4. Rutgers School of Public Health and Rutgers Cancer Institute of New Jersey. 5. Medicine. 6. Surgical Oncology. 7. Radiology, Rutgers Robert Wood-Johnson University Medical School, New Brunswick, NJ. 8. Radiation Oncology, Rutgers Cancer Institute of New Jersey.
Abstract
OBJECTIVES: The survival of patients with metastatic colorectal cancer (CRC) has been increasing over recent decades due to improvements in chemotherapy and surgery. There is a need to refine prognostic information to more accurately predict survival as patients survive for any given length of time to assist multidisciplinary cancer management teams in treatment decisions. MATERIALS AND METHODS: We performed a single center retrospective analysis of patients treated with metastatic CRC (unresectable and resectable) who survived >24 months between 2005 and 2015 (N=155). Patient tumor and treatment related variables were collected. Overall survival (OS) estimates conditional on surviving >24 months were compared with actuarial survival estimates of a cohort of patients (33,104 resected, 39,382 unresected) from the National Cancer Database (NCDB). RESULTS: With a median follow-up of 44.2 months, the median OS of resected patients (n=86) was not reached. The median OS of unresected patients was 75.9 months. The conditional survival probabilities of living 1, 2, or 3 years longer after 24 months of survival are 92%, 72%, and 52%, respectively, in unresectable patients and 98%, 92%, and 89% in patients who were resected. The corresponding NCDB 1, 2, and 3 year actuarial survival was 38%, 20%, and 11% for unresected patients and 68%, 46%, and 32% for resected. CONCLUSIONS: These results indicate that CRC patients who survive 24 months with metastatic colorectal cancer have an excellent prognosis and surgery may be appropriate in a subset of patients initially deemed unresectable.
OBJECTIVES: The survival of patients with metastatic colorectal cancer (CRC) has been increasing over recent decades due to improvements in chemotherapy and surgery. There is a need to refine prognostic information to more accurately predict survival as patients survive for any given length of time to assist multidisciplinary cancer management teams in treatment decisions. MATERIALS AND METHODS: We performed a single center retrospective analysis of patients treated with metastatic CRC (unresectable and resectable) who survived >24 months between 2005 and 2015 (N=155). Patienttumor and treatment related variables were collected. Overall survival (OS) estimates conditional on surviving >24 months were compared with actuarial survival estimates of a cohort of patients (33,104 resected, 39,382 unresected) from the National Cancer Database (NCDB). RESULTS: With a median follow-up of 44.2 months, the median OS of resected patients (n=86) was not reached. The median OS of unresected patients was 75.9 months. The conditional survival probabilities of living 1, 2, or 3 years longer after 24 months of survival are 92%, 72%, and 52%, respectively, in unresectable patients and 98%, 92%, and 89% in patients who were resected. The corresponding NCDB 1, 2, and 3 year actuarial survival was 38%, 20%, and 11% for unresected patients and 68%, 46%, and 32% for resected. CONCLUSIONS: These results indicate that CRC patients who survive 24 months with metastatic colorectal cancer have an excellent prognosis and surgery may be appropriate in a subset of patients initially deemed unresectable.
Authors: Stefanie Hieke; Martina Kleber; Christine König; Monika Engelhardt; Martin Schumacher Journal: Clin Cancer Res Date: 2015-04-01 Impact factor: 12.531
Authors: Mechteld C de Jong; Carlo Pulitano; Dario Ribero; Jennifer Strub; Gilles Mentha; Richard D Schulick; Michael A Choti; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik Journal: Ann Surg Date: 2009-09 Impact factor: 12.969
Authors: Graeme J Poston; Joan Figueras; Felice Giuliante; Gennaro Nuzzo; Alberto F Sobrero; Jean-Francois Gigot; Bernard Nordlinger; Rene Adam; Thomas Gruenberger; Michael A Choti; Anton J Bilchik; Eric J D Van Cutsem; Jy-Ming Chiang; Michael I D'Angelica Journal: J Clin Oncol Date: 2008-08-18 Impact factor: 44.544
Authors: Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley Journal: Ann Surg Date: 2004-06 Impact factor: 12.969